Breast Health

Agendia’s MammaPrint Spots Ultra-Low Breast Cancer Recurrence Risks Helping Identify Women Who Could Skip Chemo

Breast cancer test maker Agendia has released new data suggesting its MammaPrint genomic diagnostic spots breast cancer patients with ultra-low risk of recurrence, who could skip chemo and are likely to keep cancer at bay for at least 20 years. This information, culled from an analysis of 70 different genes, could help oncologists tailor treatment plans for certain early-stage breast cancer cases,…

Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test

Todos Medical, a comprehensive medical diagnostics and related solutions company, today announced that it has acquired Provista Diagnostics, Inc. Provista is a medical diagnostics company based in Alpharetta, Georgia that owns the intellectual property rights to the proprietary breast cancer blood test, Videssa, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries. The…

The Breast Cancer Alliance Celebrates Its 25th Anniversary

2021 marks 25 years since Breast Cancer Alliance (BCA) was formed, during which time the Connecticut-based foundation has grown into a national fundraising powerhouse for breast cancer research, breast surgery fellowships and outreach and education supporting patients in underserved communities. From its inception, BCA’s mission has been to improve survival rates and quality of life for those impacted by breast cancer through…

Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

Hologic, a global leader in women’s health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics for approximately $230M. Biotheranostics develops and markets two highly differentiated molecular diagnostic tests for breast and metastatic cancers. “We are very pleased to complete the acquisition of Biotheranostics and look forward to working with our new colleagues to grow in the large, rapidly expanding oncology space,”…

New Research Confirms Black Women Are More Likely to Receive Inferior Breast Cancer Screening Than White Women

A comprehensive study published in the Journal of the American College of Radiology (JACR) found racial disparities in the utilization of mammography screening overall, and specifically for digital breast tomosynthesis (DBT). The study, “Outcomes by Race in Breast Cancer Screening with Digital Breast Tomosynthesis versus Digital Mammography,” reported breast cancer screening access, utilization and outcomes by race for 385,504 Asian, Black and Caucasian women…

Veteran Biotech Executive Elizabeth Cormier-May Joins Women’s Health Startup Mammogen as the Company’s New CEO

Mammogen, a women’s health startup born at the intersection of data, technology and science has announced the appointment of Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. She will begin her new role on March 1st, 2021.   In her new role, Cormier-May will lead efforts to develop, validate and commercialize the company’s flagship liquid biopsy program for…

BioAesthetics Announces a $5M Series A to Commercialize NACgraft, a Regenerative Nipple Graft for Breast Cancer Survivors

BioAesthetics Corporation today announced that it has doubled its initial Series A funding goal of $2.5 million, closed on Dec. 30, 2020, at $5 million to commercialize its NACgraft biologic matrix— a regenerative nipple graft for breast cancer survivors. BioAesthetics’ Series A was co-led by FemHealth Ventures and personally by BioAesthetics’ Director Sandra Coufal, MD, of Sibling Capital Ventures. BioAesthetics’ inaugural product, the NACgraft — for patients…

Hologic to Acquire Biotheranostics, a Leader in Molecular Tests for Breast and Metastatic Cancers

Hologic announced today that it has agreed to acquire Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments. “Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion…